- Home
- VPG vs ALT Comparison
VPG vs ALT Comparison
Compare VPG & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VPG
- ALT
- Stock Information
- Founded
- VPG 2009
- ALT 1997
- Country
- VPG United States
- ALT United States
- Employees
- VPG N/A
- ALT N/A
- Industry
- VPG Electrical Products
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- VPG Technology
- ALT Health Care
- Exchange
- VPG Nasdaq
- ALT Nasdaq
- Market Cap
- VPG 340.4M
- ALT 292.0M
- IPO Year
- VPG N/A
- ALT N/A
- Fundamental
- Price
- VPG $28.45
- ALT $3.83
- Analyst Decision
- VPG
- ALT Strong Buy
- Analyst Count
- VPG 0
- ALT 6
- Target Price
- VPG N/A
- ALT $17.40
- AVG Volume (30 Days)
- VPG 103.9K
- ALT 3.0M
- Earning Date
- VPG 08-05-2025
- ALT 08-12-2025
- Dividend Yield
- VPG N/A
- ALT N/A
- EPS Growth
- VPG N/A
- ALT N/A
- EPS
- VPG N/A
- ALT N/A
- Revenue
- VPG $295,282,000.00
- ALT $20,000.00
- Revenue This Year
- VPG N/A
- ALT N/A
- Revenue Next Year
- VPG $5.48
- ALT $761,880.20
- P/E Ratio
- VPG N/A
- ALT N/A
- Revenue Growth
- VPG N/A
- ALT N/A
- 52 Week Low
- VPG $18.57
- ALT $2.90
- 52 Week High
- VPG $30.11
- ALT $11.16
- Technical
- Relative Strength Index (RSI)
- VPG 54.91
- ALT 51.79
- Support Level
- VPG $28.22
- ALT $3.35
- Resistance Level
- VPG $29.81
- ALT $3.66
- Average True Range (ATR)
- VPG 0.87
- ALT 0.19
- MACD
- VPG 0.15
- ALT 0.07
- Stochastic Oscillator
- VPG 62.29
- ALT 86.18
About VPG Vishay Precision Group Inc.
Vishay Precision Group Inc manufactures and markets sensors, and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.